signals operating via the androgen receptor (AR, a ligand-dependent transcription factor), ultimately leading to tumor growth. 8 Studies have demonstrated that 0.5 to 1.0 nM of DHT-the concentration observed in prostatic tissue of castrate patients-is sufficient to activate the AR and androgen-regulated genes and promote cell growth. 9, 10 Together, these findings highlight the significant roles both androgen and the AR play in cancer survival in this patient population.
Various molecular mechanisms have been proposed to explain the development of CRPC, which appears to remain dependent on androgen. 11 These include increased expression and/or activity of the AR through gene mutations and upregulation of steroidogenic enzymes such as CYP17, resulting in increased androgen production. 7 AR mutations have been reported in some patients with advanced disease. 12 Some mutations found in CRPC lead to the AR losing its specificity for androgens. As a result, it begins responding to other entities including estrogens, progesterone, and perhaps even antiandrogens. 13 Gene amplification resulting in AR hyper-responsiveness, enhanced AR signal transduction independent of ligands, and activation of downstream regulatory molecules are also possible mechanisms of resistance. 8, 11 Upregulation of nuclear transcription co-activators also leads to AR-mediated gene transcription in the presence of low levels of systemic androgens or with less potent androgens. 14 Table 1 and are discussed in greater detail in the following sections.
At present, the optimal sequencing of these new agents in the treatment of CRPC remains unclear. In general, based on experience, most physicians treating metastatic CRPC will begin with sipuleucel-T (for asymptomatic and minimally symptomatic disease) and proceed to docetaxel. This can then be followed by either abiraterone or cabazitaxel. 22 Since abiraterone is administered orally and is more tolerable, patients and clinicians tend to favor this treatment prior to cabazitaxel. As additional therapies such as MDV3100 and radium-223 gain approval, the algorithms used by physicians will continue to evolve.
Novel Agents

Cabazitaxel
Cabazitaxel is a non-cross-resistant microtubule target agent that promotes tubulin assembly. The drug thereby significantly stabilizes microtubules within the prostate, conferring antitumor activity.
Preclinical studies showed positive activity of cabazitaxel over docetaxel in some chemotherapy-resistant models. 23 A Phase I trial of cabazitaxel in 25 patients with advanced solid malignancies showed promising outcomes in refractory disease as well as acceptable tolerability. 24 Neutropenia was the main dose-limiting toxicity, with non-hematologic toxicities being mild-to-moderate in severity.
In a pivotal open-label randomized Phase III trial, 755 men with metastatic CRPC, whose disease had progressed with previous hormone therapy, were treated with 10 mg oral prednisone plus either mitoxantrone (n=377) or cabazitaxel (n=378) intravenously every three weeks. 17 Median survival was 15.1 months in the cabazitaxel group versus 12.7 months in the mitoxantrone group (p<0.0001). Similarly, progression-free survival was 2.8 months and 1.4 months in the cabazitaxel and mitoxantrone groups, respectively (p<0.0001). Again, neutropenia was the major safety issue, with 82 % of subjects receiving cabazitaxel experiencing grade 3 or higher neutropenia. available. 17 An ongoing Phase III trial is comparing first-line docetaxel with two doses of cabazitaxel (25 or 20 mg/m 2 ).
Sipuleucel-T
Sipuleucel-T is a therapeutic cancer vaccine that was introduced in 2010 for men with asymptomatic or minimally symptomatic metastatic CRPC.
It is an autologous treatment in which peripheral blood mononuclear cells are collected from patients via leukapheresis and processed at an external site. The cells-which include antigen-presenting cells-are activated with a recombinant fusion protein, PA2024, which consists of a prostate antigen, prostatic acid phosphatise, and GM-CSF. 19 The enriched ex vivo product is returned and later infused back into the patient where it stimulates the immune defences against the disease.
Following encouraging survival results from small-scale randomized, placebo-controlled studies, 25, 26 a Phase III double-blind, multicenter trial was performed with 512 subjects with metastatic CRPC using overall survival as the primary endpoint. 19 Previous studies had used time to progression as the primary endpoint and had shown no significant differences between treatment and control; however, a survival advantage had been observed. In the present study, the sipuleucel-T group demonstrated a survival advantage (relative reduction of 22 % in the risk of death) compared with placebo (hazard ratio 0.78; p=0.03).
This corresponded to a 4.1-month difference in median survival (25.8 months with sipuleucel-T versus 21.7 months with placebo). Again, median time to disease progression was not significantly different between the two groups, suggesting that overall survival is a superior endpoint. The therapy was generally well tolerated, with 31.7 % of sipuleucel-T-treated subjects experiencing serious adverse events compared with 35.1 % in the placebo group. Negative effects more commonly observed in the treatment group included chills, fever, and headache.
19 Surprisingly, changes in levels of prostate-specific antigen (PSA) and progression-free survival were not observed, making outcome predictions with sipuleucel-T use particularly challenging.
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Abiraterone Acetate CYP17 (cytochrome P450 17 alpha-hydroxylase) is a steroidogenic enzyme essential in the production of systemic testosterone, contributing to the disease progression pathway through androgen synthesis.
Administered orally, abiraterone, selectively and irreversibly inhibits this enzyme, thereby significantly reducing the amount of testosterone in patients. 27 While gonadotropin-releasing hormone (GnRH) agonists and /or antagonists can substantially reduce testosterone levels secreted by the testicles, they are not sufficient in blocking production from the adrenal glands and some prostate cells that continue to synthesize testosterone.
Abiraterone suppresses this extragonadal testosterone generation, almost eliminating measurable systemic levels of the male hormone. 28, 29 Feedback loop activation of the mineralocorticoid pathway could be mitigated by low dose corticosteroids.
Abiraterone is currently the only FDA-approved hormonal therapeutic option for patients with metastatic CRPC who have progressed following docetaxel. 30 Its approval resulted from the positive findings of several clinical trials. In particular, a Phase III study was conducted that randomized 1,195 docetaxel-refractory CRPC patients to prednisone plus either abiraterone or placebo in a 2:1 ratio. 20 Overall survival was longer in the abiraterone group versus the placebo group (14.8 months versus 10.9 months, respectively; hazard ratio 0.65; p<0.001). The treatment group also demonstrated superior outcomes for all secondary endpoints (time to PSA progression, progression-free survival, and PSA response rate). In general, treatment with abiraterone was well tolerated. Adverse events that were reported more frequently in abiraterone subjects than in those receiving placebo included mineralocorticoid-related effects such as fluid retention (31 %), hypokalemia (17 %), and hypertension (10 %). 20 While this treatment is currently only indicated in the post-docetaxel setting, it is expected to be approved for pre-docetaxel therapy as well, based on recent findings presented this year.
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Agents in Development
MDV3100
MDV3100 is an orally administered small molecule AR antagonist that binds to the AR with a higher affinity than previous AR-blocking agents such as bicalutamide. This suppresses AR translocation into the nucleus, recruitment of transcription co-activators, and DNA binding. 32 Following positive results of MDV3100 from an early Phase I/II study, 33 several Phase III clinical trials are currently under way. 34, 35 In particular, the AFFIRM (A study evaluating the efficacy and safety of investigational drug MDV3100 without concurrent prednisone in men with advanced CRPC) trial is examining this agent in patients post-docetaxel. Results illustrate a survival benefit with MDV3100 compared with placebo (18.4 months versus 13.6 months, hazard ratio 0.631; p<0.0001). 36, 37 Moreover, MDV3100 met all secondary endpoints (which included radiographic progression-free survival, soft tissue response rate, and time to PSA progression [all p<0.0001]) with statistical significance.
Based on these data, the study was halted early and treatment offered to the placebo arm. Overall, MDV3100 demonstrated a favorable safety profile; common side effects consisted of fatigue, diarrhea, and hot flushes; serious adverse events were all lower in the MDV3100 group than in the placebo group. With these promising findings, MDV3100 is expected to receive FDA approval in the near future. A second Phase III trial to evaluate the treatment in chemotherapy-naive patients is currently ongoing.
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Radium-223
Compared with the two available β-emitting radiopharmaceutical agents (strontium-89 and samarium-153 EDTMP, used mainly for palliation) radium-223 can induce double-stranded DNA breaks in tumors with less deleterious penetration into surrounding tissues. 2 This α-emitting therapy has been previously studied in Phase I and Phase II trials, where it exhibited minimal toxicity and a trend toward improved survival. 38, 39 This led to further research in the Phase III setting, with an estimated primary completion date of October 2012. 40 In particular, radium-223 is being investigated in patients with advanced CRPC and symptomatic bone metastases. Early findings announced in press releases indicate that the primary endpoint of improved overall survival has been met and the tolerability profile is consistent with previous studies. 41 Updated data show that radium-223 improved overall survival by 44 % (hazard ratio 0.695; p<0.0001), corresponding to a median benefit of 3.6 months (14.9 months in patients given treatment versus 11.3 months in those given placebo). 41, 42 It was therefore concluded that radium-223 may become a new standard of care for CRPC patients with bone metastases.
Rationale for Combining Therapies
Considering the different modes of action of the various available treatments to target tumor cells in the CRPC patients, it would be sensible to combine therapies with the goal of producing superior results to those obtained with single agents alone. For example, abiraterone works by decreasing androgen production. However, any testosterone that remains in circulation may still trigger AR activity and result in cancer growth. Therefore, the addition of MDV3100 to the regimen may enhance clinical outcomes by acting directly on the AR and blocking any interaction that may lead to adverse downstream signaling.
Further research is required to test this and similar hypotheses with complementary products, as well as determine optimal combinations.
Challenges may include a more severe toxicity profile and continued safety analyses are needed monitor this. At present, several trials are under way to evaluate different combinations in CRPC, including docetaxel plus abiraterone. 43 As findings from combination studies begin to emerge, physicians and researchers will develop a better sense of which algorithms may be best suited for their patients as well as of potential safety concerns.
Agents in Earlier Stages of Development
Other androgen synthesis inhibitors (TAK-700) and AR antagonists Additionally, cabozantinib, a small molecule tyrosine kinase inhibitor targeting c-Met and vascular endothelial growth factor receptor-2, is undergoing Phase III evaluation based on promising Phase II data. 44 Phase III trials are investigating outcomes of the combination of custirsen (a novel antisense agent against clusterin) and chemotherapeutic agents.
Summary and Conclusion
Several novel targeted therapies were recently introduced-cabazitaxel, sipuleucel-T, and abiraterone acetate-and others are in late-stage development, including MDV3100 and radium-223. This has and will continue to change the face of CRPC treatment, significantly improving overall survival. For the most part, therapeutic development has focused on inhibiting steroidogenesis and any subsequent downstream effects. As the therapies target different aspects of the disease progression pathway, it may be practical to combine complementary agents to optimize results. The optimal sequencing of these agents and biomarkers to predict benefits should be a major focus of research for the future management of CRPC. Exploiting circulating tumor cells and novel modalities to better assess tumor burden is also important.
Research into this area, together with a better understanding of the biology and mechanisms of resistance coupled with emerging biomarkers, will help inform management decisions and will ultimately improve clinical outcomes. n
